Literature DB >> 22403070

Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China.

Libo Liang1, Qunhong Wu, Lijun Gao, Yanhua Hao, Chaojie Liu, Yanguang Xie, Hong Sun, Xinglu Yan, Fabin Li, Honghai Li, Hongxia Fang, Ning Ning, Yu Cui, Liyuan Han.   

Abstract

BACKGROUND: The rapid spread of multidrug-resistant tuberculosis (MDR-TB) has attracted global concerns. This study aimed to identify factors contributing to the high prevalence of MDR-TB in China's Heilongjiang province.
METHODS: A cross-sectional survey following the WHO/International Union Against Tuberculosis and Lung Disease guidelines was conducted with consecutive recruitment of patients with TB in 30 counties selected at random in Heilongjiang in 2004. A total of 1995 patients were tested for MDR-TB. Factors associated with MDR-TB were identified through multilevel models and traditional logistic regression analysis, along with in-depth interviews with nine patients, five healthcare managers and four doctors.
RESULTS: 241 patients (12%) were identified with MDR-TB. The retreatment patients were 5.48 times (95% CI 4.04 to 7.44) more likely to have MDR-TB than newly diagnosed patients. The patients who were treated with isoniazid and rifampin for >180 days were 4.82 times (95% CI 2.97 to 7.81) more likely to develop MDR-TB than those treated <180 days. Age and delay in initiating TB treatment were associated with MDR-TB. Financial burden, poor knowledge and side effects of TB treatment were perceived by the interviewees as influencing factors. Lack of coordination of services, unsatisfactory supervision of treatment and infection control jeopardised the control of MDR-TB.
CONCLUSIONS: Inappropriate treatment is the most important influencing factor of MDR-TB. Increasing people's awareness of TB, early detection and appropriate treatment of patients with TB should become a priority, which requires strong commitment and collaboration among health organisations and greater compliance with TB treatment guidelines by service providers and patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22403070     DOI: 10.1136/thoraxjnl-2011-200018

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  41 in total

Review 1.  Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

Authors:  Satria A Prabowo; Matthias I Gröschel; Ed D L Schmidt; Alena Skrahina; Traian Mihaescu; Serap Hastürk; Rotislav Mitrofanov; Edita Pimkina; Ildikó Visontai; Bouke de Jong; John L Stanford; Père-Joan Cardona; Stefan H E Kaufmann; Tjip S van der Werf
Journal:  Med Microbiol Immunol       Date:  2012-11-10       Impact factor: 3.402

2.  Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.

Authors:  Ilia Bykov; Olga Dyachenko; Pavel Ratmanov; Huan Liu; Libo Liang; Qunhong Wu
Journal:  BMC Infect Dis       Date:  2022-07-13       Impact factor: 3.667

3.  Identification of Risk Factors of Multidrug-Resistant Tuberculosis by using Classification Tree Method.

Authors:  Dixin Tan; Bin Wang; Xuhui Li; Xiaonan Cai; Dandan Zhang; Mengyu Li; Cong Tang; Yaqiong Yan; Songlin Yu; Qian Chu; Yihua Xu
Journal:  Am J Trop Med Hyg       Date:  2017-09-21       Impact factor: 2.345

4.  Drug resistance patterns of Mycobacterium tuberculosis complex and associated factors among retreatment cases around Jimma, Southwest Ethiopia.

Authors:  Kedir Abdella; Ketema Abdissa; Wakjira Kebede; Gemeda Abebe
Journal:  BMC Public Health       Date:  2015-07-02       Impact factor: 3.295

5.  Role of a GenoType MTBDRplus line probe assay in early detection of multidrug-resistant tuberculosis at a Brazilian reference center.

Authors:  C S Feliciano; M M P Nascimento; L M P Anselmo; R H C Pocente; F Bellissimo-Rodrigues; V R Bollela
Journal:  Braz J Med Biol Res       Date:  2015-06-30       Impact factor: 2.590

6.  Are free anti-tuberculosis drugs enough? An empirical study from three cities in China.

Authors:  Shanquan Chen; Hui Zhang; Yao Pan; Qian Long; Li Xiang; Lan Yao; Henry Lucas
Journal:  Infect Dis Poverty       Date:  2015-10-28       Impact factor: 4.520

7.  Are we doing enough to stem the tide of acquired MDR-TB in countries with high TB burden? Results of a mixed method study in Chongqing, China.

Authors:  Ying Li; John Ehiri; Eyal Oren; Daiyu Hu; Xingneng Luo; Ying Liu; Daikun Li; Qingya Wang
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

8.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Authors:  Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671

9.  Risk Factors for Multidrug-Resistant Tuberculosis among Patients with Pulmonary Tuberculosis at the Central Chest Institute of Thailand.

Authors:  Charoen Chuchottaworn; Vipa Thanachartwet; Piamlarp Sangsayunh; Thu Zar Myint Than; Duangjai Sahassananda; Manoon Surabotsophon; Varunee Desakorn
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

10.  Multidrug-Resistant Tuberculosis in Patients with Chronic Obstructive Pulmonary Disease in China.

Authors:  Jiang-Nan Zhao; Xian-Xin Zhang; Xiao-Chun He; Guo-Ru Yang; Xiao-Qi Zhang; Wen-Gen Xin; Huai-Chen Li
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.